Pharmacoepigenomics in colorectal cancer: A step forward in predicting prognosis and treatment response

Kim M. Smits, Arjen H G Cleven, Matty P. Weijenberg, Laura A E Hughes, James G. Herman, Adriaan P. De Brune, Manon Van Engeland

Research output: Contribution to journalArticle

Abstract

Despite therapeutic innovations and increasing education on lifestyle to prevent colorectal cancer, it is still one of the most common cancer types, and for men the second cause of cancer-related death. Lately, much attention has been given to identify molecular markers involved in colorectal cancer prognosis and treatment with the aim to develop a more accurate classification system based on (epi)genetic alterations and, in addition, find markers that could potentially enhance management of colorectal cancer by predicting treatment response in advance. Although many genetic markers have been claimed to have prognostic or predictive influence, results are often inconclusive and, with some exception, they are not used in standard practice. Epigenetic alterations have received less attention although they are probably even more interesting as they can potentially be reversed through drug treatment. This review describes the current knowledge on the prognostic and predictive value of epigenetic markers in colorectal cancer.

Original languageEnglish (US)
Pages (from-to)1903-1916
Number of pages14
JournalPharmacogenomics
Volume9
Issue number12
DOIs
StatePublished - Dec 2008

Fingerprint

Colorectal Neoplasms
Epigenomics
Second Primary Neoplasms
Therapeutics
Genetic Markers
Life Style
Education
Pharmaceutical Preparations
Neoplasms

Keywords

  • colorectal cancer
  • epigenetics
  • pharmacoepigenomics
  • pharmacogenetics
  • prognosis
  • treatment outcome

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Smits, K. M., Cleven, A. H. G., Weijenberg, M. P., Hughes, L. A. E., Herman, J. G., De Brune, A. P., & Van Engeland, M. (2008). Pharmacoepigenomics in colorectal cancer: A step forward in predicting prognosis and treatment response. Pharmacogenomics, 9(12), 1903-1916. https://doi.org/10.2217/14622416.9.12.1903

Pharmacoepigenomics in colorectal cancer : A step forward in predicting prognosis and treatment response. / Smits, Kim M.; Cleven, Arjen H G; Weijenberg, Matty P.; Hughes, Laura A E; Herman, James G.; De Brune, Adriaan P.; Van Engeland, Manon.

In: Pharmacogenomics, Vol. 9, No. 12, 12.2008, p. 1903-1916.

Research output: Contribution to journalArticle

Smits, KM, Cleven, AHG, Weijenberg, MP, Hughes, LAE, Herman, JG, De Brune, AP & Van Engeland, M 2008, 'Pharmacoepigenomics in colorectal cancer: A step forward in predicting prognosis and treatment response', Pharmacogenomics, vol. 9, no. 12, pp. 1903-1916. https://doi.org/10.2217/14622416.9.12.1903
Smits KM, Cleven AHG, Weijenberg MP, Hughes LAE, Herman JG, De Brune AP et al. Pharmacoepigenomics in colorectal cancer: A step forward in predicting prognosis and treatment response. Pharmacogenomics. 2008 Dec;9(12):1903-1916. https://doi.org/10.2217/14622416.9.12.1903
Smits, Kim M. ; Cleven, Arjen H G ; Weijenberg, Matty P. ; Hughes, Laura A E ; Herman, James G. ; De Brune, Adriaan P. ; Van Engeland, Manon. / Pharmacoepigenomics in colorectal cancer : A step forward in predicting prognosis and treatment response. In: Pharmacogenomics. 2008 ; Vol. 9, No. 12. pp. 1903-1916.
@article{3fa8e390d8db4454bd0f8cfc2874b4b0,
title = "Pharmacoepigenomics in colorectal cancer: A step forward in predicting prognosis and treatment response",
abstract = "Despite therapeutic innovations and increasing education on lifestyle to prevent colorectal cancer, it is still one of the most common cancer types, and for men the second cause of cancer-related death. Lately, much attention has been given to identify molecular markers involved in colorectal cancer prognosis and treatment with the aim to develop a more accurate classification system based on (epi)genetic alterations and, in addition, find markers that could potentially enhance management of colorectal cancer by predicting treatment response in advance. Although many genetic markers have been claimed to have prognostic or predictive influence, results are often inconclusive and, with some exception, they are not used in standard practice. Epigenetic alterations have received less attention although they are probably even more interesting as they can potentially be reversed through drug treatment. This review describes the current knowledge on the prognostic and predictive value of epigenetic markers in colorectal cancer.",
keywords = "colorectal cancer, epigenetics, pharmacoepigenomics, pharmacogenetics, prognosis, treatment outcome",
author = "Smits, {Kim M.} and Cleven, {Arjen H G} and Weijenberg, {Matty P.} and Hughes, {Laura A E} and Herman, {James G.} and {De Brune}, {Adriaan P.} and {Van Engeland}, Manon",
year = "2008",
month = "12",
doi = "10.2217/14622416.9.12.1903",
language = "English (US)",
volume = "9",
pages = "1903--1916",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Pharmacoepigenomics in colorectal cancer

T2 - A step forward in predicting prognosis and treatment response

AU - Smits, Kim M.

AU - Cleven, Arjen H G

AU - Weijenberg, Matty P.

AU - Hughes, Laura A E

AU - Herman, James G.

AU - De Brune, Adriaan P.

AU - Van Engeland, Manon

PY - 2008/12

Y1 - 2008/12

N2 - Despite therapeutic innovations and increasing education on lifestyle to prevent colorectal cancer, it is still one of the most common cancer types, and for men the second cause of cancer-related death. Lately, much attention has been given to identify molecular markers involved in colorectal cancer prognosis and treatment with the aim to develop a more accurate classification system based on (epi)genetic alterations and, in addition, find markers that could potentially enhance management of colorectal cancer by predicting treatment response in advance. Although many genetic markers have been claimed to have prognostic or predictive influence, results are often inconclusive and, with some exception, they are not used in standard practice. Epigenetic alterations have received less attention although they are probably even more interesting as they can potentially be reversed through drug treatment. This review describes the current knowledge on the prognostic and predictive value of epigenetic markers in colorectal cancer.

AB - Despite therapeutic innovations and increasing education on lifestyle to prevent colorectal cancer, it is still one of the most common cancer types, and for men the second cause of cancer-related death. Lately, much attention has been given to identify molecular markers involved in colorectal cancer prognosis and treatment with the aim to develop a more accurate classification system based on (epi)genetic alterations and, in addition, find markers that could potentially enhance management of colorectal cancer by predicting treatment response in advance. Although many genetic markers have been claimed to have prognostic or predictive influence, results are often inconclusive and, with some exception, they are not used in standard practice. Epigenetic alterations have received less attention although they are probably even more interesting as they can potentially be reversed through drug treatment. This review describes the current knowledge on the prognostic and predictive value of epigenetic markers in colorectal cancer.

KW - colorectal cancer

KW - epigenetics

KW - pharmacoepigenomics

KW - pharmacogenetics

KW - prognosis

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=61549091202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549091202&partnerID=8YFLogxK

U2 - 10.2217/14622416.9.12.1903

DO - 10.2217/14622416.9.12.1903

M3 - Article

C2 - 19072647

AN - SCOPUS:61549091202

VL - 9

SP - 1903

EP - 1916

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 12

ER -